DE69813868T2 - Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten - Google Patents

Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten Download PDF

Info

Publication number
DE69813868T2
DE69813868T2 DE69813868T DE69813868T DE69813868T2 DE 69813868 T2 DE69813868 T2 DE 69813868T2 DE 69813868 T DE69813868 T DE 69813868T DE 69813868 T DE69813868 T DE 69813868T DE 69813868 T2 DE69813868 T2 DE 69813868T2
Authority
DE
Germany
Prior art keywords
cells
tgf
sle
production
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813868T
Other languages
German (de)
English (en)
Other versions
DE69813868D1 (de
Inventor
A. David HORWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Application granted granted Critical
Publication of DE69813868D1 publication Critical patent/DE69813868D1/de
Publication of DE69813868T2 publication Critical patent/DE69813868T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69813868T 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten Expired - Lifetime DE69813868T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
US64507P 1997-11-05
PCT/US1998/023584 WO1999025366A1 (en) 1997-11-05 1998-11-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (2)

Publication Number Publication Date
DE69813868D1 DE69813868D1 (de) 2003-05-28
DE69813868T2 true DE69813868T2 (de) 2004-03-04

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813868T Expired - Lifetime DE69813868T2 (de) 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Country Status (11)

Country Link
US (1) US6228359B1 (enExample)
EP (1) EP1028738B1 (enExample)
JP (1) JP4309047B2 (enExample)
AT (1) ATE238061T1 (enExample)
AU (1) AU747767B2 (enExample)
CA (1) CA2309115C (enExample)
DE (1) DE69813868T2 (enExample)
DK (1) DK1028738T3 (enExample)
ES (1) ES2198774T3 (enExample)
PT (1) PT1028738E (enExample)
WO (1) WO1999025366A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
ES2311462T3 (es) * 1999-05-05 2009-02-16 University Of Southern California Uso de citocinas y mitogenos para inhibir las respuestas inmunes patologicas.
ATE431399T1 (de) * 1999-09-01 2009-05-15 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
ATE460475T1 (de) 2000-04-11 2010-03-15 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
CN102971416B (zh) 2010-04-22 2018-03-30 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
EP2763692A2 (en) 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
WO2013173076A1 (en) 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
WO1999025366A1 (en) 1999-05-27
CA2309115C (en) 2010-10-19
DE69813868D1 (de) 2003-05-28
ES2198774T3 (es) 2004-02-01
DK1028738T3 (da) 2003-08-11
AU747767B2 (en) 2002-05-23
ATE238061T1 (de) 2003-05-15
AU1382799A (en) 1999-06-07
JP4309047B2 (ja) 2009-08-05
US6228359B1 (en) 2001-05-08
EP1028738A1 (en) 2000-08-23
PT1028738E (pt) 2003-08-29
EP1028738B1 (en) 2003-04-23
CA2309115A1 (en) 1999-05-27
JP2001523443A (ja) 2001-11-27

Similar Documents

Publication Publication Date Title
Gurish et al. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell
Lum et al. In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-cell and B-cell deficiencies in patients with and without chronic graft-versus-host disease
Islam et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans
US20100221209A1 (en) Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses
JP2008174564A (ja) 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用
JP4309047B2 (ja) 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
JP2007175062A (ja) 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
Selman et al. Effect of lung T lymphocytes on fibroblasts in idiopathic pulmonary fibrosis and extrinsic allergic alveolitis.
Jones et al. Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex--matched bone marrow allografts
Raiden et al. Human platelets produce granulocyte-macrophage colony-stimulating factor and delay eosinophil apoptosis
Schreiber et al. Effect of levamisole on the human monocyte IgG receptor
Streeter et al. CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease
DE69928407T2 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
DE10392933B4 (de) Verwendung von CD152+ T Zellen zur Behandlung von Krankheiten des rheumatischen Formenkreises
WO1997039108A1 (de) Verfahren zur herstellung und vermehrung von lymphozyten
Morhenn et al. [35] Isolation of epidermal langerhans cells
EP1291020A2 (en) Use of cytokines and mitogens to inhibit pathological immune responses
Shiiba et al. A novel role for accessory cells in T cell-dependent B cell differentiation
Steiner et al. S100B secretion by human CD8+ T cells activates monocytes and granulocytes: novel crosstalk between the adaptive and innate immune systems
Santoni et al. Characterization of corynebacterium parvum-induced suppressor cells of mouse NK and ADCC activity
Brander et al. Lipid Chemoattractant Receptor BLT1 Defines 4 The Leukotriene B
Brander et al. The Leukotriene B4 Lipid Chemoattractant Receptor BLT1 Defines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition